Health · 1 sources covering this

STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·54m ago
STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
Medical mystery at the AHA conference: A Novartis drug lowered a risk marker for cardiovascular disease but did not lower chance of heart attack or stroke.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/6bff3f842b0e1c32bdfb0bf6000b73b45bb815cd"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy"></iframe>

STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

How 1 sources are covering this

STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

More from Health

A promising new medicine against heart disease fails unexpectedly

STAT+: Despite Novo drug’s failure, cardiologists say they will still pursue anti-inflammatories

This teen boy set out to get people talking about periods. He's now a Diana honoree

Our Reporters Discuss Healthcare Costs — And What Changes the Midterms May Portend

Reader

Trust & legal

Across the network